Azacitidine

Catalog No.S1782 Synonyms: NSC 102816

Azacitidine  Chemical Structure

Molecular Weight(MW): 244.2

Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Size Price Stock Quantity  
In DMSO USD 130 In stock
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 7 Publications

4 Customer Reviews

  • R-2HG treatment or chemotherapeutic treatment, especially their combinations, decrease MYC levels in leukemic cells (using MONOMAC-6 as a representative). AZA:Azacitidine.

    Cell, 2018, 172(1-2):90-105. Azacitidine purchased from Selleck.

    Cells were treated with 50 µM AZA and 2 different concentrations of each HDACi for 72 h before cell viability was determined. Data is represented as percent in comparison to vehicle (DMSO) treated cells (set to 100%).

    Epigenetics, 2015, 10(5): 431-45. Azacitidine purchased from Selleck.

  • (A) The graph shows percentage of human CD45+ leukemic cells in mouse blood. At time 0, mice were injected with MV4;11 cells. The arrow indicates when drug treatment began. (B) Kaplan-Meier plot shows the percentage of mice surviving following treatment. The p-value for median survival between different treatment groups (by ANOVA) is<0.0001. The mice treated with the combination of azacitidine and panobinostat were disease-free until they were sacrificed 18 months post cell injection.

    Leuk Res, 2017, 58:91-97. Azacitidine purchased from Selleck.

    Dose response curves for azacitidine from 3-5 independent experiments performed in triplicates were generated using GraphPad Prism software. The calculated IC50s are shown.

    Leuk Res, 2018, 58:91-97. Azacitidine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Azacitidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.
Targets
DNA methyltransferase [1]
(Cell-free assay)
In vitro

Azacitidine is widely used to demonstrate the correlation between loss of methylation in specifc gene regions and activation of the associated genes. After incorporation into DNA, Azacitidine inhibits DNA methyltransferase noncompetitively, causing a block in cytosine methylation in newly replicated DNA but not in resting, nondividing cells. [1] Azacitidine induces differentiation of Friend Erythroleukemia Cell C3H10T1/2 with myotube formation. [2] Azacitidine can be activated to the nucleoside triphosphate and incorporate into both DNA and RNA, leading to inhibition of DNA, RNA and protein synthesis in normal eukaryotic cells and in cancer cell lines, which could finally leads to cell death. Azacitidine also inhibits the incorporation of purine metabolites into macromolecules. Azacitidine inhibits the L1210 cells growth with IC50 and of 0.019 μg/mL. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Raji  NFLtV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV[wMlEuPTBizszN MoO0NVIuPzJiaB?= M2\rS4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MlrzNlYyOzN{NE[=
Jurkat  MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLFNE4yNTVyIN88US=> Mo\kNVIuPzJiaB?= Mnm3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NVPic414OjZzM{OyOFY>
CA46 NX;td4RuTnWwY4Tpc44hSXO|YYm= NX3kXZIzOjEEoNM1US=> MnzROFghcA>? NIPjOoZqdmO{ZXHz[ZPDqFCWUFyxxsBuWk6DIHX4dJJme3Orb36= NV;CZY9xOjZzM{OyOFY>
Raji  MYDGeY5kfGmxbjDBd5NigQ>? M4T4dlE2yqEEtV2= M1S1N|Q5KGh? MkXrbY5kemWjc3XzxsBRXFCOMdMgcXJPSSCneIDy[ZN{cW:w M1fT[|I3OTN|MkS2
Jurkat  NGPvbmNHfW6ldHnvckBCe3OjeR?= NXSzSYJxOy53wrFCuW0> M2fuSVQ5KGh? M3XVWolv[3KnYYPld:KhWFSSTEJCpI1TVkFiZYjwdoV{e2mxbh?= MXyyOlE{OzJ2Nh?=
MDA-MB-231 NHTXTnBHfW6ldHnvckBCe3OjeR?= NGH4d3AyNzJwNT:1JO69VQ>? NXHBNZRmPDhiaB?= M4PBeIRm[3KnYYPld{B1cGViUGTQUlEzKGW6cILld5Nqd25iYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDYEoN88UUA1QMLiaB?= M1vOeVI2QDF5MkK5
MDA-MB-231 Mnr0SpVv[3Srb36gRZN{[Xl? MYqxM|IvPS93IN88US=> MWi0PEBp NHuxR5dqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDFMYNi\GincnnuJI1TVkFiYYSgeIhmKGOxbnPldo51emG2aX;uJI9nKDJwNdMg{txO\m:{IES4xsBp NXfXWWY3OjV6MUeyNlk>
MDA-MB-231 MmGxSpVv[3Srb36gRZN{[Xl? NIPTUJoyNzJwNT:1JO69VQ>? NYqxb4ZzOjRxNEigbC=> NEfRSIxqdmS3Y3XzJEB{cWewaX\pZ4FvfCCSQWLQJINt\WG4YXflJIFnfGW{IES4JIg> Ml3aNlU5OTd{Mkm=
MCF-7 MWLGeY5kfGmxbjDBd5NigQ>? M13aeFEwOi53L{Wg{txO NVfJTm51OjRxNEigbC=> MkLCbY5kemWjc3XzJHBCWlBiY3zlZZZi\2YEoB?= MYSyOVgyPzJ{OR?=
MDA-MB-231  M2LGNWZ2dmO2aX;uJGF{e2G7 NEH6NlMyNzJwNT:1JO69VQ>? NELU[2ozPC92ODDo MmrqbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJI1qWk6DLUGyOEBifCC2aHWgZ49v[2W{boTyZZRqd25ib3[gOUDPxE1? NEnXcm0zPThzN{KyPS=>
A498 MYHGeY5kfGmxbjDBd5NigQ>? MoT6NVAhyrWP NXy5dYdrPzJiaB?= M2\zOYlv\HWlZYOgeIhmKEGGQV3UV|E5KGenbnWg[ZhxemW|c3nvci=> MnuzNlU2PjlyOE[=
CaKI-2 M3vSOWZ2dmO2aX;uJGF{e2G7 NV34So96OTBiwsXN M1fhO|czKGh? MmHjbY5lfWOnczD0bIUhSUSDTWTTNVgh\2WwZTDlfJBz\XO|aX;u MkjYNlU2PjlyOE[=
Ketr-3 NIj5dY5HfW6ldHnvckBCe3OjeR?= MUKxNEDDvU1? NEHVZok4OiCq NF\ucZVqdmS3Y3XzJJRp\SCDRFHNWHMyQCCpZX7lJIV5eHKnc4Ppc44> NYft[YIxOjV3NkmwPFY>
A253 NFjy[5VHfW6ldHnvckBCe3OjeR?= MWixNEDDvU1? NVHhS|BIOC12IHS= NUDpUYl5cW6lcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Ywhd2ZidHjlJG0{WsLiYX\0[ZIhOjRiaB?= NF[wenkzPTR6NUWzOi=>
A253 MlLmSpVv[3Srb36gRZN{[Xl? NEPOdWkyOCEEtV2= MUW3NkBp M4Kwe4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdCCxZjD0bIUhVTOUIHnuJIJwfGhibXXtZpJidmViYX7kJIN6fG:|b3zpZ{BxemWyYYLheIlwdnN? MXKyOVQ5PTV|Nh?=
A253 NFGxcXNHfW6ldHnvckBCe3OjeR?= Mn;pNVAhyrWP MUmwMVQh\A>? M4r2U5Jm\HWlZYOgeIhmKDVvbXX0bJlt[3m2b4PpcoUh[2:wdHXueC=> M1fvS|I2PDh3NUO2
PC3 MljBSpVv[3Srb36gRZN{[Xl? MVuwMlIh|ryPwrC= NIX2XVM1KGR? NW\S[IxUcW6lcnXhd4V{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gTWdHSlB5LDDTSnJROSCjbnSgV2xEPkFzNTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> M2X4TVI2PDd5M{Sw
MCF7 Mln1SpVv[3Srb36gRZN{[Xl? NH3CNFgxNjNizszNxsA> MUG0JIQ> NVO0SJJKcW6lcnXhd4V{KHSqZTDn[Y5mKGW6cILld5Nqd25ib3[gTWdHSlB5LDDTSnJROSCjbnSgV2xEPkFzNTDjc41jcW6nZDD3bZRpKEeVS{GyOi=> MnP1NlU1Pzd|NEC=
PC3 NUfYZVNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe3e5kxNjJizszNxsA> MYW0JIQ> MXLk[YNz\WG|ZYOgeIhmKGOnbHyg[5Jwf3SqIITvJFIxNjNnIHPvcYJqdmWmIIfpeIghT1ONMUK2 NFLpZ44zPTR5N{O0NC=>
MCF7 NGXXfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ToZlAvOyEQvF5CpC=> MVi0JIQ> MX3k[YNz\WG|ZYOgeIhmKGOnbHyg[5Jwf3SqIEK0MlgmKGOxbXLpcoVlKHerdHigS3NMOTJ4 NHjJ[HMzPTR5N{O0NC=>
BGC-823 MkHnSpVv[3Srb36gRZN{[Xl? MkXDOeKh|ryP Mnn2O|IhcA>? MVzk[YNz\WG|ZYOgeIhmKFCUTD2zJJBzd3SnaX6gcIV3\Wxic3nncoln[2GwdHz5 NIjsZYkzPTR5NUezNy=>
MKN28 M{XzZWZ2dmO2aX;uJGF{e2G7 NUXpbnZ4PcLizszN NVv0e2hTPzJiaB?= NVvOfnhx\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? M33YW|I2PDd3N{Oz
SGC-7901 M{e4V2Z2dmO2aX;uJGF{e2G7 MYe1xsDPxE1? NFzK[G04OiCq NYfSWVlJ\GWlcnXhd4V{KHSqZTDQVmwuOyCycn;0[YlvKGyndnXsJJNq\26rZnPhcpRtgQ>? MlLiNlU1PzV5M{O=
MKN45 NE[ybIhHfW6ldHnvckBCe3OjeR?= NGfyfHc2yqEQvF2= MmLEO|IhcA>? M1XTU4Rm[3KnYYPld{B1cGViUGLMMVMheHKxdHXpckBt\X[nbDDzbYdvcW[lYX70cJk> NFS2fpQzPTR5NUezNy=>
BGC-823 M4DQZWZ2dmO2aX;uJGF{e2G7 M{LqfFXDqM7:TR?= NVOx[|MxPzJiaB?= MmrO[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= MnfENlU1PzV5M{O=
MKN28 MkHoSpVv[3Srb36gRZN{[Xl? M4\UPFXDqM7:TR?= MVe3NkBp MoWy[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiUGLMMVMhe2mpbnnmbYNidnSueR?= NXHJXnhNOjV2N{W3N|M>
SGC-7901 MkjsSpVv[3Srb36gRZN{[Xl? MkXEOeKh|ryP NVmzfFBVPzJiaB?= MYnk[YNz\WG|ZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBw\iCSUlytN{B{cWewaX\pZ4FvfGy7 MlLSNlU1PzV5M{O=
MKN45 NE\wR4lHfW6ldHnvckBCe3OjeR?= NYjreYlGPcLizszN M1\vNVczKGh? NWflSlZ{\GWlcnXhd4V{KHSqZTDtVm5CKGW6cILld5Nqd25ib3[gVHJNNTNic3nncolncWOjboTsfS=> MlfpNlU1PzV5M{O=
HREC NG\nO|lHfW6ldHnvckBCe3OjeR?= MXu1M|ExyqEQvF2= NUP0fYRIPDhiaB?= M3nReYlv\HWlZYOgVGVFTiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2HrfVI2OzV{N{S3
HRPE NF\vOHJHfW6ldHnvckBCe3OjeR?= NIHtcWY2NzFywrFOwG0> M{HvPFQ5KGh? MUTpcoR2[2W|IGDFSGYhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MnnsNlU{PTJ5NEe=
HREC NUXPXWdrTnWwY4Tpc44hSXO|YYm= NXS0XHVCPS9zMNMg{txO NH\BTGY1QCCq NY[xdppn\G:5bj3y[Yd2dGG2ZYOgc4YhXkWJRjygTWNCVS1zIDjuc5QheHKxdHXpckBt\X[nbDDpckBJWlCHIHPlcIx{MSxiSVytNe6zKGSxc3Wt[IVx\W6mZX70cJk> NUTje4JqOjV|NUK3OFc>
HRPE NXiwXmxyTnWwY4Tpc44hSXO|YYm= MoTqOU8yOMLizszN M1ruclQ5KGh? MWjkc5dvNXKnZ4XsZZRmeyCxZjDWSWdHNCCLTD2x{tItKGGwZDDNUXAzKGSxc3Wt[IVx\W6mZX70cJk> M1\keVI2OzV{N{S3
MSCs NVvtbVhXTnWwY4Tpc44hSXO|YYm= NEfyZVgyOCEQvF2= MmTnNlQhcA>? MYLwdo9ud3SnczD0bIUh[2:vbXn0cYVvfCCxZjDNV2N{KHSxIH35c4NiemSrYXyg[Iln\mW{ZX70bYF1cW:w M2KyPVI2OzVzM{m1
HL-60 MV;GeY5kfGmxbjDBd5NigQ>? MYq1JO69VQ>? Ml3vO|IhcA>? M2XLXWROW09? MofId4lodmmoaXPhcpRtgSC3cILl[5Vt[XSnczDaUmY{QDJiZYjwdoV{e2mxbh?= Mln4NlU{OTlyNEm=
MV4-11 MWPGeY5kfGmxbjDBd5NigQ>? M4rQeVUh|ryP NVLvPY5vPzJiaB?= M3fnNGROW09? NFjWPVZ{cWewaX\pZ4FvfGy7IIXwdoVofWyjdHXzJHpPTjN6MjDlfJBz\XO|aX;u NWfkSnVyOjV|MUmwOFk>
A2780 MmfpSpVv[3Srb36gRZN{[Xl? MmjDOUDDvU4EoB?= MXq3JIQ> M{O4dolv[3KnYYPld{BFVkFibXX0bJlt[XSrb36gcIV3\Wx? NFTROGwzPTJ7OU[5OC=>
CP70 MVrGeY5kfGmxbjDBd5NigQ>? MVi1JOK2VcLi MWq3JIQ> MnLtbY5kemWjc3XzJGRPSSCvZYTofYxifGmxbjDs[ZZmdA>? MVKyOVI6QTZ7NB?=
A2780 MmjESpVv[3Srb36gRZN{[Xl? NILa[3c2KML3TdMg MVO3JIQ> MVH3[YFs\W6|IITo[UBt\X[nbDDv[kBu\XSqeXzheIlwdg>? NYLvR4Z2OjV{OUm2PVQ>
CP70 NUTNenJ{TnWwY4Tpc44hSXO|YYm= NXzGNJVpPSEEtV5CpC=> M{mz[|ch\A>? NEX2[pR4\WGtZX7zJJRp\SCuZY\lcEBw\iCvZYTofYxifGmxbh?= MUKyOVI6QTZ7NB?=
OCM3 NUf0RpBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLKO5UxNjVxMT:yJO69VQ>? MVu3JIQ> MY\EUXNQ MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> Mo\lNlUyPDZ7OEG=
92.1 M4fiT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3OydFAvPS9zL{Kg{txO MlPhO{Bl NVTK[5NwTE2VTx?= Mn3TbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NV\4Z21ROjVzNE[5PFE>
OCM1 MkG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKwMlUwOS9{IN88US=> NGPyNIw4KGR? Ml;wSG1UVw>? NXL0NndLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIjtOIszPTF2Nkm4NS=>
OMM1 M1fJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy5fFcxNjVxMT:yJO69VQ>? M1LH[Fch\A>? M3jNTmROW09? NWDD[mV6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NXruSXZGOjVzNE[5PFE>
Mel 285 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEP0T2YxNjVxMT:yJO69VQ>? NF75ZWo4KGR? M{LBUGROW09? NUfuXHI5cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGHacIozPTF2Nkm4NS=>
Mel 290 NVT4cXVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnDOm0xNjVxMT:yJO69VQ>? M37wXFch\A>? M2\WNWROW09? Moj1bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NF\wc4QzPTF2Nkm4NS=>
OCM3 NXftZlQ2TnWwY4Tpc44hSXO|YYm= NGftWZQxNjVxMTFOwG0> NIT3e2Q1QCCq NXLQbYNQTE2VTx?= MYTk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 NH3mTJAzPTF2Nkm4NS=>
92.1 NIDDSZVHfW6ldHnvckBCe3OjeR?= MlrCNE42NzFizszN MV60PEBp NWLCUmptTE2VTx?= MmK2[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? MXeyOVE1Pjl6MR?=
OCM1 MnnBSpVv[3Srb36gRZN{[Xl? MWewMlUwOSEQvF2= MonhOFghcA>? NUDVW|J1TE2VTx?= Mo[w[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? M1THd|I2OTR4OUix
OMM1 M{HtbWZ2dmO2aX;uJGF{e2G7 NH:2VoMxNjVxMTFOwG0> MluwOFghcA>? MnnwSG1UVw>? MkfQ[IVkemWjc3XzJINtd26xZ3XubYNqfHliZH;z[U1l\XCnbnTlcpRtgQ>? NEjKVZkzPTF2Nkm4NS=>
Mel 285 MVXGeY5kfGmxbjDBd5NigQ>? NVrIRXBZOC53L{Gg{txO MnjPOFghcA>? NIjxOmdFVVOR NXLzfGJ2\GWlcnXhd4V{KGOub37v[4VvcWOrdImg[I9{\S2mZYDlcoRmdnSueR?= NWO1e5pqOjVzNE[5PFE>
Mel 290 MXHGeY5kfGmxbjDBd5NigQ>? NIjib4ExNjVxMTFOwG0> NVjrfWVlPDhiaB?= MYDEUXNQ MYjk[YNz\WG|ZYOgZ4xwdm:pZX7pZ4l1gSCmb4PlMYRmeGWwZHXueIx6 MVuyOVE1Pjl6MR?=
OCM3 NFKyOYdHfW6ldHnvckBCe3OjeR?= NFvvXHQxNjVxMTFOwG0> M3;4bVQ5KGh? MWjEUXNQ MUHk[YNz\WG|ZYOgbY53[XOrb36g[I9{\SCmZYDlcoRmdnSuedMg Ml;kNlUyPDZ7OEG=
Mel 290 NXPFdFNJTnWwY4Tpc44hSXO|YYm= MUiwMlUwOSEQvF2= M{PKN|Q5KGh? MUHEUXNQ NWPLU|l4\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? MVuyOVE1Pjl6MR?=
OMM1 MX3GeY5kfGmxbjDBd5NigQ>? MV:wMlUwOSEQvF2= NYD6UmJ1PDhiaB?= MlX3SG1UVw>? NXS1OGZr\GWlcnXhd4V{KGmwdnHzbY9vKGSxc3Wg[IVx\W6mZX70cJnDqA>? MkTQNlUyPDZ7OEG=
OCM1 NGq4V|NE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFW4fm0xNjVxMTFOwG0> MlzUOUBl Mn\2SG1UVw>? NGLLNVhl\WO{ZXHz[ZMhemGmaXH0bY9vNWmwZIXj[YQh[2WubDD2bYFjcWyrdImgbY5pcWKrdHnvci=> M4nqW|I2OTR4OUix
92.1 NU[xNI1SS2WubDDWbYFjcWyrdImgRZN{[Xl? MYqwMlUwOSEQvF2= M334PVUh\A>? NHuye3VFVVOR MYfk[YNz\WG|ZYOgdoFlcWG2aX;uMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHliaX7obYJqfGmxbh?= MmnENlUyPDZ7OEG=
OCM1 NWKzWGJFTnWwY4Tpc44hSXO|YYm= MYKwMlUwOSEQvF2= MkfCOFghcA>? Mn\sSG1UVw>? M4nBO4NifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= NWrFT2NDOjVzNE[5PFE>
OCM3 M2DQXGZ2dmO2aX;uJGF{e2G7 M3rkPVAvPS9zIN88US=> NHH6emI1QCCq NVWydYt3TE2VTx?= M1rH[INifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= NUDUV3plOjVzNE[5PFE>
92.1 NFn4OGVHfW6ldHnvckBCe3OjeR?= NH;lO2sxNjVxMTFOwG0> MUe0PEBp MXnEUXNQ M{\1R4NifXOnczDncI9j[WxiRF7BJIh6eG:vZYTofYxifGmxbjDheEBNNTFicnXw[YF1KGyxY3m= M1Ti[VI2OTR4OUix
IMR32 M1jkPWZ2dmO2aX;uJGF{e2G7 NFnKclg{KM7:TR?= NUfzOVY5PzJiaB?= NHG5ZlBFVVOR NXPyVmNFcW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 M{jv[|I2OTB2OEWw
IMR5-75 MlHPSpVv[3Srb36gRZN{[Xl? NFHxV3E{KM7:TR?= NED6eok4OiCq NGrRe4dFVVOR M1zyXYlv\HWlZYRCpJAyQS2LTlu0[OKh\XiycnXzd4lwdsLic3nncolncWOjboTsfS=> NIrQdVQzPTFyNEi1NC=>
Be(2)-C MYHGeY5kfGmxbjDBd5NigQ>? MUmzJO69VQ>? NXe3eo5LPzJiaB?= MYHEUXNQ NYTaN4l{cW6mdXPld:KheDF7LVnOT|RlyqCneIDy[ZN{cW:wwrDzbYdvcW[rY3HueIx6 MYmyOVExPDh3MB?=
Bxpc-3 NWfoW2RLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjQOU8yOCEQvF2= MmeyNlQwPDhxN{KgbC=> MkjKbY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gc4YhSniyYz2zJINmdGy|IHnuJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XK| M1;tblI2ODZzN{Ox
Bxpc-3 MVjBdI9xfG:|aYOgRZN{[Xl? MkW0OU8yOCEQvF2= NEfSVmEzPC92OD:3NkBp Mnq3bY5lfWOnczDhdI9xfG:|aYOgbY4hfGmvZT2gZY5lKGOxbnPldo51emG2aX;uJI1idm6ncoO= Mnz5NlUxPjF5M{G=
Bxpc-3 NXTkXVg3TnWwY4Tpc44hSXO|YYm= NIn6b2g2NzFyIN88US=> M1\sTFI1NzR6L{eyJIg> NU\mSoJr\GWlcnXhd4V{KM7{LXPheIVvcW5iZYjwdoV{e2mxbjDh[pRmeiB{NDDo NXnzSpI6OjVyNkG3N|E>
Bxpc-3 NV\0OFJRTnWwY4Tpc44hSXO|YYm= NFTWfoU2NzFyIN88US=> MkD3NlQwPDhxN{KgbC=> M2C2S4Rm[3KnYYPld{BkgWOuaX7ENUBmgHC{ZYPzbY9vKGG2IITo[UBkd26lZYLueJJifGmxbjDv[kAyOCEQvF2= NWPaXmFpOjVyNkG3N|E>
Bxpc-3 NUDDcVdnTnWwY4Tpc44hSXO|YYm= NHrNZ5Y2NzFyIN88US=> Ml[4NlQwPDhxN{KgbC=> M1LtZYRwf25vcnXneYxifGWVIHOtcZlkKG2UTlGg[ZhxemW|c3nvckBqdiC2aX3lMUBidmRiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXydy=> NWHBfmtFOjVyNkG3N|E>
HL-60 NX;Z[|dET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWSxMlAh|ryP M4[2XlQ5KGh? M3HQ[5Nq\26rZnnjZY51dHliaX7obYJqfHNiSFytOlAh[2WubDDndo94fGkEoB?= MUSyOVA2OTFzOR?=
HL-60 NEi5fGFHfW6ldHnvckBCe3OjeR?= NVW5Tm15OS5yIN88US=> MV:0PEBp M17WRYlv[3KnYYPld{BxOjGZQV[xM2NKWDIEoHHu[EBk[XOyYYPlMVMh\XiycnXzd4lwdsLi NYfLXowxOjVyNUGxNVk>
HL-60 M3LJOGZ2dmO2aX;uJGF{e2G7 MYCxMlAh|ryP NXzWRXJwPDhiaB?= NEfVNWVl\WO{ZXHz[ZMhSmOuLYjMJIV5eHKnc4Ppc47DqHOrZ37p[olk[W62bIm= NUX5eY9FOjVyNUGxNVk>
HuTu-80  NXXscJRqTnWwY4Tpc44hSXO|YYm= NVnLUZNqOS93L{GwJO69VQ>? MojjOFgwPzJiaB?= NHH1cFFqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhcHWvYX6gUnBEOUxzIH3SUmEhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWmyOFkxPDB4Mh?=
Caco2  NUXqbHlzTnWwY4Tpc44hSXO|YYm= MYWxNEDPxE1? NGe4UlU1QCCq MXjpcoNz\WG|ZYOgUnBEOUxzIHX4dJJme3Orb36= NGixOFQzPDlyNEC2Ni=>
HepG2  NWDLcoVZTnWwY4Tpc44hSXO|YYm= NV3FUVEyOC1{NTFOwG0> NHPSTY8zPCCq Mlj0[IVkemWjc3XzJJN2[nSrbHnzbY4wc2W6aX6geJlx\SB7IDjQR3NMQSlicILveIVqdiCuZY\lcJMh\G:|ZTDk[ZBmdmSnboTsfS=> NXThcpJqOjR6NUW2OFY>
HepG2  Ml20SpVv[3Srb36gRZN{[Xl? M2K4NFAuOjVizszN NFHVR3QzPCCq MYnpcoNz\WG|ZYOgcI94KGSnboPpeJkhdGmyb4Dyc5RmcW5icnXj[ZB1d3JiKFzEUHIqKGenbnWg[ZhxemW|c3nvcuKh MYKyOFg2PTZ2Nh?=
HepG2  NICxc|BHfW6ldHnvckBCe3OjeR?= NV3SVIVqOTBizsztxsA> MkjFNE0zPCCq MVvk[YNz\WG|ZYRCpHBEW0t7wrDhcoTDqEiPR1PSxsBmgHC{ZYPzbY9vKGGwZDDpcoNz\WG|ZYOgUGRNWiCneIDy[ZN{cW:wIHHmeIVzKDZiaB?= NY\ZTlVYOjR6NUW2OFY>
HepG2  NXHISGsxTnWwY4Tpc44hSXO|YYm= NUPZRVFxOTBizszt MV:yOEBp NXLpRmlEeHKxbX;0[ZMh[3m2b4PvcIlkKG6ndYTyZYwhdGmyaXSgZYNkfW23bHH0bY9vKGmwZHXw[Y5l\W62bImgc4Yh\XixZ3Xuc5V{KGyrcH;wdo91\Wmwcx?= M4Pab|I1QDV3NkS2
HepG2  NGfId|JHfW6ldHnvckBCe3OjeR?= NF:5TGwyOCEQvH2= M{D5dVI1KGh? MkDpdJJmfmWwdIOgV3JGSlBicILvZ4V{e2mwZx?= MUCyOFg2PTZ2Nh?=
HC45  MUTGeY5kfGmxbjDBd5NigQ>? M3Tpb|XDvU4EoB?= MYC0JIQ> MVny[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? MlrYNlQ4PjJ6MEm=
CNDT2  NHXFbHZHfW6ldHnvckBCe3OjeR?= MnnyOeK2VcLi Ml;yOEBl MVjy[YR2[2W|IITo[UBu\XSqeXzheIlwdiCuZY\lcJMhd2ZiV1nGNUwhWDF4LDDDXGNNOTRuIF7LXFLjiJN|LDDDSGgyNCCOQV3BNUwh[W6mIFPUUm5DOQ>? NU[zO2gxOjR5NkK4NFk>
CNDT2  MW\GeY5kfGmxbjDBd5NigQ>? NG\6UII2yrWPwrC= MmC0OEBl NXTPcYdscW6lcnXhd4V{KGenbnWg[ZhxemW|c3nvckBw\sLiV1nGNUwhWDF4LDDDSGgyNMLiTFHNRVEtyqCjbnVCpGNVVk6EMR?= NXjYboxXOjR5NkK4NFk>
T-cells MnPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXCOU8zOCEQvF2= MXewMVQ5KGh? NYjDbnBMcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NIjKNG0zPDd3N{K4Ny=>
CD3+ T-cells M{nUZ2Z2dmO2aX;uJGF{e2G7 MofkOU8zOCEQvF2= MUW0PEBp MV;1dJJm\3WuYYTld{BxOTViZYjwdoV{e2mxbh?= MXuyOFc2PzJ6Mx?=
CD4+ T-cells NXHmUYlKTnWwY4Tpc44hSXO|YYm= NEDmUpk2NzJyIN88US=> NF7KcWI1QCCq NILXV492eHKnZ4XsZZRmeyCyMUWg[ZhxemW|c3nvci=> M2HFTlI1PzV5Mkiz
CD8+ T-cells MVfGeY5kfGmxbjDBd5NigQ>? M4H5clUwOjBizszN NYXKU4RtPDhiaB?= NWP3e5ExfXC{ZXf1cIF1\XNicEG1JIV5eHKnc4Ppc44> MYSyOFc2PzJ6Mx?=
CD3+ T-cells NFvuUYNHfW6ldHnvckBCe3OjeR?= M{naVVUwOjBizszN NFnlNVc1QCCq NH;FdXV2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCIT2jQNy=> NWi2NFdNOjR5NUeyPFM>
CD4+ T-cells MlnkSpVv[3Srb36gRZN{[Xl? MYm1M|IxKM7:TR?= MlPhOFghcA>? MUX1dJJm\3WuYYTld{B1cGViZYjwdoV{e2mxbjDv[kBHV1iSMx?= NUD3UIRIOjR5NUeyPFM>
CD4+ T-cells MWLGeY5kfGmxbjDBd5NigQ>? NWG5NlBOPS9{MDFOwG0> NWK4eoZNPDhiaB?= MlfrdoVlfWOnczDURmVVOcLibWLORUBmgHC{ZYPzbY9v NVTUZ3hKOjR5NUeyPFM>
CD4+ T-cells MnL5SpVv[3Srb36gRZN{[Xl? Mo\4OU8zOCEQvF2= NGflSnU1QCCq NITOUo52eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\sLiUl;S{tN1yqB? NULtPHNEOjR5NUeyPFM>
CD4+ T-cells M1HLTGZ2dmO2aX;uJGF{e2G7 NXfCPZU6PS9{MDFOwG0> M2PXVlQ5KGh? NYe4d|BzcW6qaXLpeJMhdWWvb4L5JHQu[2WubIO= NHnjUo8zPDd3N{K4Ny=>
CD8+ T-cells MUnGeY5kfGmxbjDBd5NigQ>? NGC5XIw2NzJyIN88US=> M4PQZlQ5KGh? NIr2b5RqdmirYnn0d{Bu\W2xcomgWE1k\Wyucx?= MWiyOFc2PzJ6Mx?=
CD3+ T-cells M1LzcmZ2dmO2aX;uJGF{e2G7 NXrYbFBqPSEQvF2= NU\TPW52PDhiaB?= NF;KOndz\WS3Y3XzJIxwdmdvdHXycUBu\W2xcomgZ4VtdCCyaHXuc5R6eGV? MkLvNlQ4PTd{OEO=
U937 NU\hZZVUSXCxcITvd4l{KEG|c3H5 MXqxNEDPxE1? MkTHO|IhcA>? NGHze4JqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7 MWCyOFY5ODh4NR?=
HL-60 MXLBdI9xfG:|aYOgRZN{[Xl? NFLIPFMyOCEQvF2= MYG3NkBp M2q2NYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl? NWW0cohSOjR4OEC4OlU>
MCF7 NVf5e4wyTnWwY4Tpc44hSXO|YYm= NHLLZXc2KM7:TR?= NH\rVXQ1QCCqwrC= MWLkbZNxdGG7czDz[Yxm[3SrdnWgeI95cWOrdImgeI94[XKmIIP1d5BmdmSnZDDNR2YuPyClZXzsdy=> MWSyOFY{OzN3MB?=
MCF7 NVHRXItyTnWwY4Tpc44hSXO|YYm= M3;SWVExKM7:TR?= NHewRnkzPCCqwrC= M{HUcolv\HWlZYOgeIhmKGOuZXH2ZYdmKG:oIHPhd5Bie2ViNzDhcoQhWEGUUNMg NIfzfGgzPDZ|M{O1NC=>
MCF7 M3;FbGZ2dmO2aX;uJGF{e2G7 MmPjNQKBmzBwNTFOwG3DqA>? MmfYO{Bl NWe2OYdIcW6qaXLpeJMhfGinIHfyc5d1cCCPQ1[tO{B1fW2xcoPwbIVz\XNiaX6gd5V{eGWwc3nvckBkfWy2dYLld:Kh NUfwZVZqOjR4M{OzOVA>
MCF7 NFq1PY5HfW6ldHnvckBCe3OjeR?= MlrkNE42KM7:TdMg NHXyNnUyPCCm MlHpdoVlfWOnczD0bIUhe2m8ZTDv[kBOS0ZvNzDjc4xwdmmnczDlcYJm\GSnZDDpckB{d2[2IHHnZZI> NGjGTlQzPDZ|M{O1NC=>
MCF7 M2LlZWZ2dmO2aX;uJGF{e2G7 NIX4ZXAxNjB34pETNlAh|ryP NX20S4lmOSCm MonzdoVlfWOnczD0bIUh[2yxbnHsJJN2en[rdnHsJI9nKE2FRj23JINmdGy|IHnuJI1wdm:uYYnldkBkfWy2dYLldy=> Mof6NlQ3OzN|NUC=
T47D  M4Dac2Z2dmO2aX;uJGF{e2G7 MmDNNE42KM7:TR?= M1X6[lQh\A>? Mlj5bY5pcWKrdIOgeJVud3K|cHjldoUh\m:{bXH0bY9v MXuyOFY{OzN3MB?=
MCF7 M3XTZmZ2dmO2aX;uJGF{e2G7 MnOxNE426oDVMUCg{txO M2rUU|Q5KGkEoB?= NWPTSnVXcW6qaXLpeJMhfGinIHfhdEBkdG:|dYLlJIlvKHSqZTD3c5Vv\CCqZXHsbY5oKGG|c3H5 MnfCNlQ3OzN|NUC=
MCF7 MYfGeY5kfGmxbjDBd5NigQ>? NFL1VFYxNzFyIN88US=> MYiyOEBp NV6xT|hMcW6qaXLpeJMhfGinIHHjeIl3cXS7IH;mJG1OWDl? MnnUNlQ3OzN|NUC=
MDA-MB-231  MmrRSpVv[3Srb36gRZN{[Xl? NF;XSW4xNjYkgKOxNEDPxE1? NGqwdZg{PiCq NUDxc2hocW6qaXLpeJMhfGinIH3p[5JifGmxbh?= M3S2W|I1PjN|M{Ww

... Click to View More Cell Line Experimental Data

In vivo Azacitidine inhibits polynucleotide synthesis in leukemic BDF1 mice. [3] Azacitidine (3 mg/kg, i.p.) increases the mean survival time in leukemic BDF1 mice inoculated with Ll210 ascites tumor cells. Azacitidine markedly suppresses all enzymes activity in the polyamine-biosynthetic pathway, including ornithine decarboxylase activity. putrescine-dependent S-adenosyl-L-methionine decarboxylase activity, and spermidine-dependent S-adenosyl-L-methionine decarboxylase activity. Azacitidine also inhibits the accumulations of polyamines in leukemic mice. [4]

Protocol

Cell Research:[3]
+ Expand
  • Cell lines: Leukemia L1210 cell
  • Concentrations: 0.15 μg/mL
  • Incubation Time: 3 days
  • Method: 5 mL of L1210 cells (5 × 103 cells/mL) are incubated with Azacitidine at 37 ℃ for 3 days. Cell number is determined twice a day for 3 days by means of a Model A Coulter counter.
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: BDF1 mice bearing lymphoid leukemia L1210
  • Formulation: Dissolved in 0.85% NaC1 solution immediately prior to use
  • Dosages: 3 mg/kg
  • Administration: Daily i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 48 mg/mL warmed (196.56 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.2
Formula

C8H12N4O5

CAS No. 320-67-2
Storage powder
in solvent
Synonyms NSC 102816

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03486353 Withdrawn Myelodysplastic Syndrome (MDS) Fujifilm Pharmaceuticals U.S.A. Inc. October 2019 Phase 2
NCT03486353 Withdrawn Myelodysplastic Syndrome (MDS) Fujifilm Pharmaceuticals U.S.A. Inc. October 2019 Phase 2
NCT03850418 Not yet recruiting Myeloid Malignancy Henry Ford Health System June 1 2019 Phase 2
NCT03850418 Not yet recruiting Myeloid Malignancy Henry Ford Health System June 1 2019 Phase 2
NCT03862157 Not yet recruiting Acute Myeloid Leukemia|Atypical Chronic Myeloid Leukemia BCR-ABL1 Negative|Chronic Eosinophilic Leukemia Not Otherwise Specified|Chronic Myelomonocytic Leukemia|Chronic Neutrophilic Leukemia|Dysplasia|Essential Thrombocythemia|FGFR1 Gene Rearrangement|Myelodysplastic Syndrome|Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis|Myelodysplastic/Myeloproliferative Neoplasm Unclassifiable|Myeloid Neoplasm|Myeloproliferative Neoplasm|Myeloproliferative Neoplasm Unclassifiable|Overt Primary Myelofibrosis|PDGFRA Gene Rearrangement|PDGFRB Gene Rearrangement|Polycythemia Vera|Polycythemia Vera Post-Polycythemic Myelofibrosis Phase|Prefibrotic/Early Primary Myelofibrosis M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 31 2019 Phase 1|Phase 2
NCT03628209 Not yet recruiting Osteosarcoma|Osteosarcoma in Children|Osteosarcoma Recurrent|Sarcoma H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb May 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is the vehicle (30% Propylene glycol, 5% Tween 80, 65% D5W) for Azacitidine (Catalog No.S1782) safe for subcutaneous dosing?

  • Answer:

    S1782 in 30% Propylene glycol+5% Tween 80+65% D5W at 30mg/ml is a suspension. If you are going to administrate this compound for oral gavage, it is fine. But if you administrate the drug via injection, you need a clear solution and S1782 can be dissolved in 5% DMSO+30% PEG 300+ddH2O at 10mg/ml clearly.

DNA Methyltransferase Signaling Pathway Map

Tags: buy Azacitidine | Azacitidine supplier | purchase Azacitidine | Azacitidine cost | Azacitidine manufacturer | order Azacitidine | Azacitidine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID